Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: A review of efficacy, safety, and outcomes

Figure 1 How proprotein convertase subtilisin/kexin type 9 inhibitors enhance low-density lipoprotein (LDL) receptor recycling on hepatocytes, thereby reducing plasma LDL cholesterol levels and mitigating atherosclerosis risks in peripheral artery disease. Key actions include blocking proprotein convertase subtilisin/kexin type 9-low-density lipoprotein receptor interactions and promoting anti-inflammatory and plaque-stabilizing effects, which collectively decrease cardiovascular events in peripheral artery disease (PAD) patients.